<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Downregulation of ERCC1 Boosts Efficacy of Platinum-Based NSCLC Chemotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-8</style></pages><abstract><style  face="normal" font="default" size="100%">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) may reduce excision repair cross-complementing group 1 (ERCC1) gene expression, potentially enhancing sensitivity to platinum-based chemotherapy in patients with non—small cell lung cancer (NSCLC), according to results from a poster presented by Cheong et al. [Cheong HT et al. J Thorac Oncol 2014].</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>